We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
The receipt of this permission paves way for the launch of BREZTRI AEROSPHERE in India
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Themis will market this drug with the brand name REMITHEM.
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Subscribe To Our Newsletter & Stay Updated
